



Curriculum Vitae Europass

Informazioni personali

Nome / Cognome **Domenica Caramazza**
Indirizzo **Viale Borri 57, 21100 Varese**
Telefono **0332278115**
Fax **0332278612**
E-mail **domenica.caramazza@asst-settelaghi.it**

Cittadinanza **Italiana**

Luogo e Data di nascita

Sesso **Femminile**

Codice Fiscale

Occupazione desiderata/Settore professionale

Dirigente medico, Medico specialista in Ematologia presso l'Unità Operativa di Ematologia del Presidio di Varese

Esperienza professionale

Da aprile 1011 ad oggi dirigente medico, specialista ematologo c/o l'ematologia dell'Azienda Ospedaliera "Ospedale di Circolo e Fondazione Macchi" di Varese, Viale Borri 57, 21100 Varese, Italia.

Lavoro o posizione ricoperti **Dirigente medico**
Principali attività e responsabilità **Attività clinica svolta nella diagnosi e cura delle emopatie**
Nome e indirizzo del datore di lavoro **A.O. ASST Sette Laghi, Varese**
Tipo di attività o settore **Divisione di Ematologia, attività clinica e di ricerca**

Istruzione e formazione

Titolo della qualifica rilasciata

2011 Titolo di Dottore di Ricerca in "Scienze e tecnologie diagnostiche in ambito biomedico" (vincitrice di concorso per borsa di studio triennale 2008-2010) conseguito presso L'Università degli Studi di Palermo in data 21/03/2011
2007 Diploma di Specializzazione in Ematologia conseguito presso l'Università degli Studi di Palermo il 21/11/07 con la votazione di 50/50 e Lode

PUBBLICAZIONI PER ESTESO

1. Cantoni S, Carpenedo M, Mazzucconi MG, De Stefano V, Carrai V, Ruggeri M, Specchia G, Vianelli N, Pane F, Consoli U, Artoni A, Zaja F, D'Adda M, Visentin A, Ferrara F, Barcellini W, **Caramazza D**, Baldacci E, Rossi E, Ricco A, Ciminello A, Rodeghiero F, Nichelatti M, Cairoli R. *Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers*. Am J Hematol. 2017 Oct 6.
2. Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjan JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, **Caramazza D**, Merli M, Pietra D, Casalone R, Rotunno G, Barbui T, Cazzola M, Vannucchi AM. *A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis*. Leukemia. 2017 May 31. doi: 10.1038/leu.2017.169. [Epub ahead of print] PMID:28561069
3. Passamonti F, Mora B, Giorgino T, Guglielmelli P, Cazzola M, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjan JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver R, Benevolo G, Albano F, **Caramazza D**, Rumi E, Merli M, Pietra D, Casalone R, Barbui T, Pieri L, Vannucchi AM. *Driver mutations' effect in secondary myelofibrosis: an international multicenter study based on 761 patients*. Leukemia. 2017 Apr;31(4):970-973
4. Molteni A, Riva M, Borin L, Bernardi M, Pelizzari AM, Freyrie A, Delta Porta M, Nichelatti M, Ravano E, Quaresmini G, Mariotti J, **Caramazza D**, Ubezio M, Guarco S, Gigli F, Greco R, Cairoli R, Morra E. *The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine: A retrospective analysis in ten centers of the "Rete Ematologica Lombarda"*. Leuk Res. 2016 Mar;42:21-7.
5. Passamonti F, **Caramazza D**, Mora B, Casalone R, Maffioli M. *It is time to change thrombosis risk assessment for PV and ET?* Best Pract Res Clin Haematol. 2014 Jun;27(2):121-7. doi: 10.1016/j.beha.2014.07.005. Epub 2014 Jul 18. Review.
6. Dentali F, Ageno W, Rumi E, Casetti I, Poli D, Scoditti U, Maffioli M, di Minno MN, **Caramazza D**, Pietra D, De Stefano V, Passamonti F. *Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases*. Thromb Res. 2014 Jul;134(1):41-3
7. Passamonti F, **Caramazza D**, Maffioli M. *JAK inhibitor in CALR-mutant myelofibrosis* N Engl J Med. 2014 Mar 20;370(12):1168-9
8. Passamonti F, Maffioli M, Cervantes F, Vannucchi AM, Morra E, Barbui T, **Caramazza D**, Pieri L, Rumi E, Gisslinger H, Knoops L, Kiladjan JJ, Mora B, Hollaender N, Pascutto C, Harrison C, Cazzola M. *Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts*. Blood. 2014 Mar 20;123(12):1833-5.
9. Maffioli M, Genoni A, **Caramazza D**, Mora B, Bussini A, Merli M, Giorgino T, Casalone R, Passamonti F. *Looking for CALR mutations in familial myeloproliferative neoplasms*. Leukemia. 2014 Jun;28(6):1357-60.
10. Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH, Maffioli M, **Caramazza D**, Passamonti F, Pardanani A. *CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons*. Leukemia. 2014 Jul;28(7):1472-7.
11. Merli M, Ferrario A, Basilico C, Maffioli M, **Caramazza D**, Appio L, Arcaini L, Passamonti F. *Novel agents in indolent lymphomas*. Tner Adv Hematol. 2013 Apr;4(2):133-48.
12. Passamonti F, Maffioli M, Merli M, Ferrario A, **Caramazza D**. *Clinical predictors of outcome in MPN*. Hematol Oncol Clin North Am. 2012 Oct;26(5):1101-16. doi: 10.1016/j.hoc.2012.07.009. Epub 2012 Aug 28. Review.
13. Passamonti F, Thiele J, Girodon F, Rumi E, Carobbio A, Gisslinger H, Kvasnicka HM, Ruggeri M, Randi ML, Gangat N, Vannucchi AM, Gianatti A, Gisslinger B, Müllauer L, Rodeghiero F, d'Amore ES, Bertozzi I, Hanson CA, Boveri E, Marino F, Maffioli M, **Caramazza D**, Antonioli E, Carrai V, Buxhofer-Ausch V, Pascutto C, Cazzola M, Barbui T, Tefferi A. *A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment*. Blood. 2012 Aug 9;120(6):1197-201
14. Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T, Pierce S, Jabbour E, Borthakur G, Rumi E, Pungolino E, Morra E, **Caramazza D**, Cazzola M, Passamonti F. *Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls*. Blood. 2012 Aug 9;120(6):1202-9.
15. Tefferi A, Pardanani A, Gangat N, Begna KH, Hanson CA, Van Dyke DL, **Caramazza D**, Vannucchi AM, Morra E, Cazzola M, Pereira A, Cervantes F, Passamonti F. *Leukemia risk models in primary myelofibrosis: an International Working Group study*. Leukemia. 2012 Jun;26(6):1439-41
16. Passamonti F, Maffioli M, **Caramazza D**. *New generation small-molecule inhibitors in myeloproliferative neoplasms*. Curr Opin Hematol. 2012 Mar;19(2):117-23.

17. Tefferi A, Jimma T, Gangat N, Vaidya R, Begna KH, Hanson CA, Van Dyke DL, Caramazza D, Pardanani A. Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients. *Blood*. 2011 Oct 27;118(17):4595-8.
18. Passamonti F, Maffioli M, Caramazza D, Cazzola M. Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies. *Oncotarget*. 2011 Jun;2(6):485-90.
19. Vaidya R, Caramazza D, Begna K, Gangat N, Van Dyke D.L., Hanson C.A., Pardanani A, and Ayalew Tefferi A. Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival. *Blood*. 2011 May 26;117(21):5612-5.
20. Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study. *J Clin Oncol*. 2011 Apr 1;29(10):1356-63.
21. Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, Van Dyke D, Hanson C, Wu W, Pardanani A, Cervantes F, Passamonti F, Tefferi A. DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status. *J Clin Oncol*. 2011; 29(4): 392-7.
22. Caramazza D, Begna KH, Gangat N, Vaidya R, Siragusa S, Van Dyke DL, Hanson C, Pardanani A, Tefferi A. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. *Leukemia*. 2011; 25(1): 82-8.
23. Caramazza D, Lasho TL, Finke CM, Gangat N, Dingli D, Knudson RA, Siragusa S, Hanson CA, Pardanani A, Ketterling RP, Tefferi A. *IDH* mutations and trisomy 8 in myelodysplastic syndromes and acute myeloid leukemia. *Leukemia*. 2010; 24(12): 2120-2.
24. Caramazza D, Quintini G, Abbene I, Lo Coco L, Malato A, Di Trapani R, Saccullo G, Pizzo G, Palazzolo R, Barone R, Mazzola G, Rizzo S, Ragonese P, Ardon P, Abbadessa V, Siragusa S. Rituximab for managing relapsing/refractory patients with idiopathic TTP-HUS. *Blood Transfus*. 2010; 8(3): 203-10.
25. Caramazza D, Quintini G, Abbene I, Malato A, Saccullo G, Coco LL, Di Trapani R, Palazzolo R, Barone R, Mazzola G, Rizzo S, Ragonese P, Ardon P, Abbadessa V, Siragusa S. Relapsing or refractory idiopathic thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the role of rituximab. *Transfus*. 2010 Dec;50(12):2753-60. doi: 10.1111/j.1537-2995.2010.02763.x. Review.
26. Tefferi A, Lasho TL, Abdel-Wahab O, Guglielmelli P, Patel J, Caramazza D, Pieri L, Finke CM, Kilpivaara O, Wadleigh M, Mai M, McClure RF, Gilliland DG, Levine RL, Pardanani A, Vannucchi AM. *IDH1* and *IDH2* mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. *Leukemia*. 2010; 24(7): 1302-9.
27. Patnaik MM, Lasho TL, Finke CM, Gangat N, Caramazza D, Hollan SG, Pardanani A, Knudson RA, Ketterling RP, Chen D, Hoyer JD, Hanson CA, Tefferi A. WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations. *Leukemia*. 2010; 24(7): 1283-9.
28. Caramazza D, Ketterling RP, Knudson RA, Hanson CA, Siragusa S, Pardanani A, Tefferi A. Trisomy 11: prevalence among 22,403 unique patient cytogenetic studies and clinical correlates. *Leukemia*. 2010; 24(5): 1092-4.
29. Patnaik MM, Lasho TL, Finke CM, Gangat N, Caramazza D, Siragusa S, Hanson CA, Pardanani A, Tefferi A. MPL mutation effect on JAK2 46/1 haplotype frequency in JAK2V617F-negative myeloproliferative neoplasms. *Leukemia*. 2010; 24(4): 859-60.
30. Caramazza D, Hussein K, Siragusa S, Pardanani A, Knudson RA, Ketterling RP, Tefferi A. Chromosome 1 abnormalities in myeloid malignancies: A literature survey and karyotype-phenotype associations. *Eur J Haematol*. 2010; 84(3): 191-200.
31. Patnaik MM, Caramazza D, Gangat N, Hanson CA, Pardanani A, Tefferi A. Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival. *Eur J Haematol*. 2010; 84(2): 155-8.
32. Malato A, Saccullo G, Coco LL, Caramazza D, Abbene I, Pizzo G, Casuccio A, Siragusa S. Patients requiring interruption of long-term oral anticoagulant therapy: the use of fixed sub-therapeutic doses of low-molecular weight heparin. *J Thromb Haemost*. 2010; 8(1): 107-13.
33. Caramazza D, Caracciolo C, Barone R, Malato A, Saccullo G, Cigna V, Berretta S, Schinocca L, Quintini G, Abbadessa V, Di Raimondo F, Siragusa S. Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms. *Ann Hematol*. 2009; 88(10): 967-71.

34. Siragusa S, **Caramazza D**, Malato A. *How should we determine length of anticoagulation after proximal deep vein thrombosis of the lower limbs?* *Br J Haematol*, 2009; 144(6): 832-7.
35. Siragusa S, Malato A, Lo Coco L, Cigna V, Saccullo G, Abbene I, Anastasio R, **Caramazza D**, Patti R, Arcara M, G. Di Vita G. *Gastrointestinal bleeding due to angiodysplasia in patients with type 1 von Willebrand disease: report on association and management.* *Haemophilia*, 2008; 14(1): 150-2.

Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196
"Codice in materia di protezione dei dati personali (facoltativo)".

11/10/2017 Domenica Caramazza